The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I like your optimism MaxHS, and hope you are right!
I can certainly see 2p in sight based in a fully functional research and growing facility, so perhaps by mid 2022.
Personally I think 9-13 might be a bit optimistic as that would give an mcap of between £70-100m. I think until we get an understanding of the number of plants to be grown, the size of the harvest, the market value for the harvest, and then hence the potential revenue. Until then I think we are really shooting in the air at potential share price.
I’ll be happy if we get to 4p by early 2023 by which time we should have a better understanding of revenue potential and maybe then we’ll be able make a decent stab at a forecast of share price.
Don’t get wrong, I’m very optimistic of good progress and I don’t mean for this to come across as a downer but I try to keep myself reigned in on medium to long term forecasts until I have a better understanding of the fundamentals. That said, the one thing that gives me great confidence in ANA is the size of the shareholding of MS!
Very good day today though!
Love Hemp Group PLC
("Love Hemp" or the "Company")
Love Hemp Receives Initial Amazon Order
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK's leading CBD and hemp product suppliers, is pleased to announce that it has received its initial order from Amazon.
Love Hemp was invited by Amazon to join its limited range of CBD products listed on amazon.co.uk. Following a rigorous compliance process, a number of Love Hemp SKUs have been ordered by Amazon and will be available to purchase on amazon.co.uk shortly. The Company expects this available product range to increase as the authorisation process continues.
As an Amazon Vendor, Love Hemp will also have its own dedicated virtual store through which Amazon and the Company will conduct marketing activities to drive awareness and visibility of Love Hemp products. Operating on the Amazon Vendor platform, Amazon will place orders with Love Hemp in order to fulfil consumer orders from Amazon's central depot. These orders will be shipped across the UK and into Europe.
Tony Calamita, Chief Executive Officer of Love Hemp Group commented: "Securing an invitation, and fulfilling the compliance required, to list our products on Amazon is a significant achievement for Love Hemp. It is further validation of our brand strength and product quality as well as the rapidly changing sentiment of retail giants to offer premium CBD products to their consumers.
Our presence on amazon.co.uk opens a new major online sales channel for Love Hemp. We look forward to building on this initial order and the successful opening of the Love Hemp virtual store."
ANANDA DEVELOPMENTS PLC
(“Ananda” or the “Company”)
Research Facility Construction Update
Ananda, the AQSE-listed medical cannabis company creating UK-based operations to grow and provide carbon neutral, consistent, pharmaceutical quality medical cannabis for the UK and international markets, provides the following update on the construction of its research facility.
Since the Company’s update on 6 September 2021, works have continued on schedule at the medical cannabis research growing facility being developed in the UK by DJT Plants Limited (“DJT Plants”), the Company’s 50% owned subsidiary.
As previously announced the facility footprint has been increased. To provide further detail to shareholders, it now incorporates:
a dedicated growing room for female plants (which produce the resin secreting flowers used for medicinal cannabis)
a dedicated growing room for male plants (grown to pollinate the female plants)
a dedicated plant nursery
a dedicated room for mother plants (to guarantee genetic consistency of each generation of plants)
laboratory space (for trimming plants, analysing characteristics and test work)
enlarged work rooms
The facility is also being constructed to allow for thorough cleaning and to accommodate appropriate work flows and movement of plants through the work rooms. These are requirements for Good Manufacturing Practices (“GMP”) certification, which will be applied for in due course. The facility construction management team (supplied by Ananda’s partner JE Piccaver & Co (Gedney Marsh) Limited (“JEPCO”)) is well versed in all aspects of high plant care standards, as they are required in the salad leaf industry where JEPCO operates as a large-scale speciality grower. Salad leaves are not cooked before being consumed, so the team is very familiar with the required levels of hygiene, work-flow management and deep cleaning. JEPCO operates to Red Tractor standards, which were established in 2000 and which have grown to become the UK’s biggest farm and food standards scheme, covering all aspects of food safety, traceability and environmental protection. JEPCO is also accredited under Global GAP (the Global Partnership for Safe and Sustainable Agriculture) and is a Selected Grower under the Marks & Spencer Field to Fork programme.
DJT Plants holds a licence from the Home Office of the UK Government to grow >0.2% THC cannabis for research purposes.
Excellent RNS. This should see the sp start to move up.
Kanabo Group Plc
("Kanabo" or "the Company")
Materia Receives Commercial Production Licence for Malta Facility
Kanabo Group Plc (LSE:KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, notes the recent announcement published by Materia. Kanabo are delighted that Materia's wholly-owned subsidiary, Materia Malta Operating Ltd. ("Materia Malta"), has received its Licence for the Production of Cannabis for Medicinal and Research Purposes (the "Licence") from the Malta Medicines Authority.
The receipt of the Licence is the final requirement for Materia Malta to begin commercial production and export of medical cannabis for commercial purposes. Materia Malta, which is already EU GMP certified, has an annual throughput capacity of 6,000kg, representing a potential sale value of €36M based on a blended average sales price across several key European markets.
Materia Malta has now begun the process of importing its first batch of raw material for commercial production and will begin fulfillment of its supply commitments across Europe imminently, starting with the initial target markets of Germany, Malta and the UK. The first product has already been successfully registered on the narcotics licence of Materia Deutschland GmbH ahead of its import into and across Germany.
Quote from Tony Calamita re Amazon….
“We are still waiting for them to place orders as well as approve the remainder of the range, we have been on at them daily. Honestly never known such a dysfunctional set up. It's ridiculous”
Taken from the LH Telegram group. One of the members knows Tony personally, so called him directly.
From this I’d say it looks as though Amazon are going through the setup process currently but products won’t be available for a couple of weeks if they still haven’t placed an order on LH. My guess is that the RNS will be issued on the day that the products become available to purchase.
If anyone is interested, Ananda have an Instagram page. Nothing spectacular and they don’t post often, but today they posted a couple of pics of the development work that is ongoing at the DJT Plants site. Nice to see visible progress being made.
Another positive step up the ladder…
ANANDA DEVELOPMENTS PLC
(“Ananda” or the “Company”)
DJT Plants’ Cannabis Flower approved for import into Israel
Ananda, which is creating UK-based operations to grow and provide carbon neutral, consistent, high quality medical cannabis for the UK and international markets, announces that the Government of Israel has granted a licence for cannabis flower grown at Ananda’s subsidiary, DJT Plants Limited (“DJT Plants”) to be imported into Israel. The licence is held by Cannasoul Analytics, the research company which will be analysing DJT Plants’ cannabis flower.
The purpose of obtaining an import licence at this early stage is to ensure that DJT Plants has a clear understanding of all requirements for moving cannabis flower, a controlled drug under the UK Government’s Misuse of Drugs Act 1971, from the UK into Israel. The import licence was awarded by Israel’s Department of Pharmaceutical Import and Narcotics at the Ministry of Health, and by the Ministry of Agriculture and Rural Development Plant Protection and Inspection Services. Appropriate licences will be sought under the relevant UK legislation allowing the export of cannabis flower from the UK nearer to the time of export.
In April 2020, Ananda announced that it would be collaborating with Professor Dedi Meiri, the leading global medical cannabis researcher at The Technion in Israel, to carry out detailed molecular analysis of the strains of cannabis which Ananda proposes to grow and stabilise at DJT Plants.
As part of Ananda’s research plan to stabilise 65 strains of medical cannabis and conduct field trials, future cannabis plant material grown by DJT Plants will be sent to Cannasoul Analytics, an Israel-based commercial research company formed by Professor Dedi Meiri, for analysis of cannabinoid, terpene and flavonoid profiles. It is the view of the Directors of Ananda that Israel continues to be at the forefront of global medical cannabis research and that Israel’s experts have the greatest depth of understanding of the cannabis plant at the molecular level.
Ananda’s ultimate ambition is for DJT Plants to transition to commercial growing of medical cannabis. The Board remains encouraged by progress.
Preparation of documentation continues for the acquisition of the 50% of DJT Group Limited not already owned by Ananda. This work includes the drafting of a range of supporting agreements. Further detail on the proposed acquisition is detailed in the Company’s announcement of 8 June, 2021.
Ananda’s CEO, Melissa Sturgess, commented: “We don’t underestimate the complexity of the work required to grow medical cannabis in the UK. The prize, however, is big; both from a patient care and a financial perspective. Delivering the best quality, consistent medical cannabis medicine to UK and international patients is our clear objective. We continue to work in a focused and diligent manner towards achieving our goals.”
LTB - Great list! It’s good to see all the potential milestones laid out as it serves as a reminder if good things to come!
A couple of comments…
Your first point re the Interim results. Given the MSYS financial year runs 1st Jan to 31st Dec, and the final results for 2020 weren’t released until 4th May, isn’t Sept too early for the Interims? I actually thought May was quite late for the finals but 6 months on would take you to early Nov. Have you seen a timetable which provides key investor dates? I’ve looked on the website but not found anything.
Also, would you mind if I copied your list into the MSYS Telegram group? I’ll make sure it’s attributed to you and not me! Or you could join the group and post it yourself, as currently we are only a small group and would welcome a like minded investor with your knowledge.
Yep, I get the long term aspect of Ananda but news flow and communication plans is key.
I’ve heard the Stockbox interviews and the couple of short clips by Melissa all of which are on Youtube. These provided interesting information but are not very specific on dates. I’ve also seen the presentation from 2019 which showed a loose timeline, but the other info on the website is out of date.
Re the podcasts to which you refer to, are these the ones on the Ananda channel on Youtube or something else?
I think if we do go below 0.5p, I’ll treat that as a top up opportunity.
I sincerely hope not! Very little news of major significance at the moment, so we need to be patient for now but lack of real progress and plan information is a little frustrating.
Has anyone seen any timescales for completion of the new growing facility and then a timetable to start growing and first production? It’s tangibles such as these that might start to wake up the market to ANA.
Unless we get something real that we can hang our hats on, then based on the current trend, I think an SP below 0.5p is very real in the not too distant.
Added again this morning (although trade not showing) thinking we can’t go down any further and then in comes another sell for over 5m!
Surely we must be near the bottom by now, and given the positive messages in all our recent RNS and the anticipation of what is to come we must head back up soon!?!?
Thanks Fig, but hey, life also goes on…
Your thinking around the ASIC development and identifying the right partner is a very interesting question. I assume you are thinking sale or licence for any technology QBT develop.
For an end customer needing new tech, and this is pure speculation and massive assumptions being made, could it be ARB? Interesting that in their 9th August RNS ARB stated that they had cancelled their order for new mining machines citing ‘limitations of technology’ and agreed with their supplier to leave the cash with them for a future purchase (or stock options). The question is, are they waiting for the QBT development or do they have their eyes on other developments?
Hi Fig - Thanks for your kind words. We’ve all had a tough 18 months, but losing my dad to covid in March 2020, than my mum going into long term care due to her increasing disability, and now my father-in-law under going treatment for Bladder cancer and investigations for Liver cancer, I think our family have had our fair share of ill health issues to deal with recently!
I come in here, and the Telegram groups, for my investments as they provide an interesting distraction from the day to day issues of family life but also it often provides a good source of information for learning more about companies when I don’t always have enough time to do really in-depth research myself.
Thanks for all the info above, and the links. Some very interesting reading and certainly food for thought. Assuming FG, as a professor himself, has excellent relationships with these universities, it looks increasingly probable that he has leveraged these relationships to build his team of research experts.
I’d still like to see a business professional take the CEO role, incentivised through stretching performance based share options, to drive the business, improve comms, sort out the legecy businesses and improve the investor facing aspects of the company and that would free up FG to take on a free-reign role as CTO leading his team of experts.
I was seriously considering selling out of QBT a few weeks ago, but given the most recent RNS I’m going to hang in. FG has really put himself out there now with the timelines he talks about, so I’m going to see if those timelines are hit over the next 3-6 months and then take a view from there.
Who knows, if he hits all the timescales we could easily be looking at 10p+ in that timescale, in which case we would all be very happy!
Fig - Apologies for the delay in response, elderly parents serious health issues proved a significant distraction yesterday. I’ll try to find time to review all the info above later today.
Dssloan - It’s a fair point you make, but I wasn’t so much referring to professors etc being the amateurs, more the approach of FG over the last 6 months. Having worked for a very large corporate IT provider for 30 years I guess I’m used to a more polished customer/investor facing approach. Someone commented a few weeks ago about the downside of a professor being a CEO, which I very much agree with. The business ought to be lead by business professionals and let the professors get on with the tech and research.